Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Background Information:
ABBV-744 is an orally available first-in-class highly BDII (Bromodomain II)-selective (>100 X selectivity over BDI) BET bromodomain inhibitor, currently is being investigated to treat AML and metastic castration-resistant prostate cancer (ref 1).
Reference:
1. G. S. Sheppard, et al, Discovery of ABBV-744, a first-in-class highly BDII-selective BET bromodomain inhibitor Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL.
APIM050003: ABBV-744 (ABBV744)
CAS No.: 2138861-99-9
Molecular Formula: C28H30FN3O4 ? 0.2H2O
Molecular Weight: 495.2
Purity: 99.9% by HPLC at 214 and 254 nm.
QC: HPLC-MS, 1H-NMR, and Quantitative Elemental Analysis Report.
Solubility: refer to Certificate of Analysis.
Storage: refer to Certificate of Analysis.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.